EMA Monitors CDK 4/6 Inhibitors; US Issues Serious Side Effect Warning
Executive Summary
Cases of "rare but serious" lung inflammation have been seen in breast cancer patients undergoing treatment with CDK 4/6 inhibitors. The US regulator has taken action and the European Medicines Agency is monitoring the situation in Europe.